Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$93 Mln
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
--
Debt to Equity
0.16
ROE
-0.7 %
ROCE
-59.42 %
Div. Yield
0 %
Book Value
3.15
EPS
-3.01
CFO
$-157.81 Mln
EBITDA
$-230.00 Mln
Net Profit
$-468.40 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Hillevax Inc (HLVX)
| -10.63 | 10.12 | -6.09 | -85.29 | -- | -- | -- |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Hillevax Inc (HLVX)
| -86.89 | -4.06 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of... moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda for the commercialization of any pharmaceutical products with HIL-214 compounds. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. Read more
President, CEO & Chairman of the Board
Dr. Robert M. Hershberg M.D., Ph.D.
President, CEO & Chairman of the Board
Dr. Robert M. Hershberg M.D., Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Hillevax Inc (HLVX) stood at $ 193 Mln as on 31-Dec-24
The share price of Hillevax Inc (HLVX) is $1.85 (NASDAQ) as of 25-Apr-2025 16:02 EDT. Hillevax Inc (HLVX) has given a return of -85.29% in the last 1 years.
Hillevax Inc (HLVX) has a market capitalisation of $ 93 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Hillevax Inc (HLVX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Hillevax Inc (HLVX) and enter the required number of quantities and click on buy to purchase the shares of Hillevax Inc (HLVX).
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda for the commercialization of any pharmaceutical products with HIL-214 compounds. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
The CEO & director of Dr. Robert M. Hershberg M.D., Ph.D.. is Hillevax Inc (HLVX), and CFO & Sr. VP is Dr. Robert M. Hershberg M.D., Ph.D..
There is no promoter pledging in Hillevax Inc (HLVX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Hillevax Inc (HLVX) | Ratios |
|---|---|
|
Return on equity(%)
|
-70.13
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Hillevax Inc (HLVX) was $0 Mln.
